Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.38 |
| ▸ | GLRB | P48167 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311610 | 0.81 | CA1 (0.67) | CA1CA2GABBR2GABBR1ERN1 | |
| SCHEMBL30186532 | 0.81 | CA1 (0.67) | CA1CA2GABBR2GABBR1ERN1 | |
| SCHEMBL10002045 | 0.80 | VCAM1 (0.50) | CA1CA2GLRA3GLRBGABBR2 | |
| SCHEMBL13257339 | 0.79 | VCAM1 (0.41) | CA1CA2GLRA3GLRBGABBR2 | |
| SCHEMBL8323656 | 0.75 | ERN1 (0.60) | ELANECA2PRTN3ERN1 | |
| SCHEMBL10019582 | 0.74 | VCAM1 (0.37) | CA1CA2GABBR2GABBR1MAPT | |
| SCHEMBL21114904 | 0.74 | ERN1 (0.58) | CA1CA2GLRA3GLRBGABBR2 | |
| SCHEMBL8144442 | 0.74 | CA2 (0.55) | CA1CA2GLRA3GLRBGABBR2 | |
| SCHEMBL5633091 | 0.74 | CA2 (0.40) | CA1CA2GLRA3GLRBGABBR2 | |
| SCHEMBL10019578 | 0.73 | VCAM1 (0.44) | CA1CA2GLRA3GLRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | ELANE 1041/4885CA1 2652/4885CA2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.